Structure-Guided Design of Broad-Spectrum Viral Fusion Inhibitors

Introduction

Viral entry into host cells represents the first essential step in the infection cycle and is mediated by specialized viral fusion proteins. These glycoproteins undergo dramatic conformational rearrangements to catalyze the merger of the viral envelope with the host cell membrane, a process that is both energetically favorable and highly coordinated [1]. The fusion machinery is conserved across many enveloped viruses, particularly those bearing class I fusion proteins, which include orthomyxoviruses, paramyxoviruses, filoviruses, coronaviruses, and retroviruses [1]. In veterinary medicine, these pathogens cause substantial morbidity and mortality in livestock, poultry, and companion animals. Examples include highly pathogenic avian influenza virus (H5N1) in poultry and wild birds, porcine reproductive and respiratory syndrome virus (PRRSV) in swine, and Newcastle disease virus in poultry. The structural conservation of the fusion mechanism across these diverse viral families provides a compelling rationale for the development of broad-spectrum fusion inhibitors [1, 2].

Structure-guided design leverages high-resolution three-dimensional structures of viral fusion proteins, obtained through X-ray crystallography or cryo-electron microscopy, to identify conserved binding pockets and hydrophobic grooves that are critical for the fusion process [1]. Computational methods, including molecular docking, pharmacophore mapping, and molecular dynamics simulations, are then employed to screen and optimize candidate inhibitors that can occupy these sites and prevent the conformational changes required for membrane fusion [2]. This review focuses on the biophysical principles, computational workflows, and structural determinants that underpin the design of peptide and small molecule fusion inhibitors, with an emphasis on veterinary viral pathogens.

Biophysical Basis of Viral Membrane Fusion

Viral fusion proteins exist in a metastable prefusion conformation on the virion surface. Upon binding to a host cell receptor or exposure to the acidic pH of the endosome, the protein undergoes a series of irreversible conformational changes [1]. For class I fusion proteins, the hallmark of this process is the formation of an extended, trimeric coiled-coil structure known as the prehairpin intermediate. In this state, the hydrophobic fusion peptide at the N-terminus of the protein inserts into the host cell membrane [1]. The protein then folds back upon itself, bringing the fusion peptide and the transmembrane anchor into close proximity. This refolding drives the apposition and eventual merger of the viral and cellular membranes [1]. The final, postfusion conformation is a highly stable six-helix bundle (6HB) in which three C-terminal heptad repeat (HR2) regions pack into hydrophobic grooves on the surface of the central trimeric coiled-coil formed by the N-terminal heptad repeat (HR1) regions [1].

The 6HB is an exceptionally stable structure, and its formation is the thermodynamic driving force for membrane fusion. Inhibitors that bind to the prehairpin intermediate and prevent 6HB assembly are therefore potent fusion blockers [1]. The hydrophobic grooves on the HR1 trimer represent the primary target for peptide inhibitors derived from the HR2 sequence, as well as for small molecules that can mimic the key interactions made by the native HR2 helix [1, 2].

Peptide Inhibitors Targeting Class I Fusion Proteins

The most extensively characterized class of fusion inhibitors are peptides derived from the HR2 region of viral fusion proteins. These peptides, often referred to as C-peptides, bind competitively to the HR1 trimer in the prehairpin intermediate, thereby blocking 6HB formation [1]. The prototypical example in human virology is enfuvirtide, a 36-amino acid peptide targeting HIV-1 gp41. In veterinary virology, analogous strategies have been applied to a range of pathogens. Structure-guided design has enabled the optimization of these peptides for improved potency, stability, and breadth of activity [1].

Gonepudi et al. [1] described a systematic approach to the design of peptide inhibitors targeting class I fusion proteins from multiple viral families. By aligning the HR2 sequences of diverse viruses and solving the crystal structures of their HR1 cores, the authors identified conserved structural features within the hydrophobic grooves. These grooves are lined with conserved hydrophobic residues that accommodate the side chains of the HR2 peptide at positions a and d of the heptad repeat [1]. The binding interface is characterized by extensive van der Waals contacts and a smaller number of hydrogen bonds. The authors demonstrated that peptide inhibitors could be engineered with enhanced helical propensity and optimized binding affinity through the introduction of salt bridges and the substitution of non-conserved residues with those that form more favorable contacts with the conserved groove [1].

The design workflow for peptide inhibitors typically involves the following steps:

1. Structural determination of the HR1 core trimer in its postfusion conformation via X-ray crystallography or cryo-electron microscopy.
2. Identification of the binding groove and mapping of the key hydrophobic pockets that accommodate HR2 side chains.
3. Sequence alignment of HR2 regions from multiple viral strains or species to identify conserved residues.
4. Computational mutagenesis and molecular docking to predict the binding energy of candidate peptide variants.
5. Synthesis and biophysical characterization using circular dichroism spectroscopy to assess helical content and surface plasmon resonance to measure binding affinity.
6. In vitro antiviral assays to determine the half-maximal inhibitory concentration (IC50) against target viruses.

A key challenge in peptide inhibitor design is the limited solubility and metabolic stability of peptides. Kuhn et al. [3] addressed this issue in the context of coronavirus fusion inhibitors by systematically modifying the peptide sequence to enhance aqueous solubility while retaining antiviral potency. The authors introduced charged residues at solvent-exposed positions and replaced hydrophobic residues that did not contribute directly to groove binding. This approach yielded peptide variants with significantly improved solubility profiles without a substantial loss of activity [3]. These solubility-enhancing strategies are directly transferable to the design of veterinary fusion inhibitors, where formulation and delivery constraints are often more stringent than in human medicine.

Small Molecule Fusion Inhibitors

While peptide inhibitors are highly potent, their clinical utility is limited by poor oral bioavailability, high production costs, and susceptibility to proteolytic degradation. Small molecule fusion inhibitors offer the potential for oral administration, lower manufacturing costs, and improved pharmacokinetic profiles [2]. The design of small molecule inhibitors targeting the same hydrophobic grooves on the HR1 trimer is a more challenging endeavor, as the binding interface is large and predominantly hydrophobic. Nevertheless, structure-guided approaches have yielded promising small molecule leads.

Xu et al. [2] provided mechanistic insights into the small molecule inhibition of influenza A virus entry. The influenza hemagglutinin (HA) is a class I fusion protein, and its low-pH-induced conformational change is essential for membrane fusion. Using a combination of X-ray crystallography, molecular docking, and site-directed mutagenesis, the authors identified a small molecule that binds to a conserved hydrophobic pocket in the HA stem region [2]. This pocket is distinct from the receptor-binding site and is critical for the conformational rearrangements that occur during fusion. The inhibitor stabilizes the prefusion conformation of HA, preventing the extended coiled-coil formation required for membrane fusion [2].

The molecular docking workflow employed by Xu et al. [2] involved the following steps:

1. Preparation of the receptor structure: The crystal structure of the HA trimer in its prefusion conformation was obtained from the Protein Data Bank. Water molecules and non-essential ligands were removed, and hydrogen atoms were added.
2. Binding pocket identification: A combination of computational solvent mapping and sequence conservation analysis was used to identify the druggable pocket in the HA stem.
3. Virtual screening: A library of small molecules was docked into the binding pocket using a genetic algorithm-based docking program. The scoring function evaluated van der Waals interactions, electrostatic complementarity, and desolvation penalties.
4. Hit validation: Top-ranked compounds were tested in vitro using a cell-cell fusion assay and a pseudovirus entry assay. The most potent hit was then co-crystallized with HA to confirm the binding mode.
5. Optimization: Structure-activity relationship (SAR) studies were conducted by synthesizing analogs of the hit compound and testing them in the same assays.

The co-crystal structure revealed that the inhibitor occupies a hydrophobic cavity formed by residues from the HA1 and HA2 subunits. The compound makes critical hydrogen bonds with backbone amides and side chain hydroxyl groups, as well as extensive hydrophobic contacts with conserved leucine, isoleucine, and phenylalanine residues [2]. This binding mode stabilizes the prefusion conformation and prevents the low-pH-induced dissociation of the HA1 globular head domain, which is a prerequisite for the fusogenic conformational change [2].

Pharmacophore Modeling and Binding Pocket Analysis

Pharmacophore models are three-dimensional representations of the steric and electronic features necessary for a molecule to interact with a target binding site. In the context of viral fusion inhibitors, pharmacophore models are derived from the conserved interactions observed in the crystal structures of peptide inhibitors bound to the HR1 trimer [1]. The key pharmacophoric features typically include:

• Hydrophobic centers: Corresponding to the side chains of leucine, isoleucine, valine, and phenylalanine residues that insert into the hydrophobic grooves.
• Hydrogen bond donors: Backbone amide NH groups and side chain amino groups that form hydrogen bonds with carbonyl oxygens in the groove.
• Hydrogen bond acceptors: Carbonyl oxygens and side chain carboxylates that accept hydrogen bonds from backbone amides or arginine/lysine side chains in the target.
• Aromatic rings: Phenylalanine, tyrosine, and tryptophan side chains that engage in pi-stacking or cation-pi interactions with conserved aromatic residues in the groove.

These pharmacophore features are used to screen virtual libraries of small molecules to identify compounds that match the spatial arrangement of the key interactions. The resulting hits are then subjected to molecular docking to refine the binding pose and estimate the binding free energy [2].

The binding pocket pharmacophore for the HR1 groove of class I fusion proteins is characterized by a series of deep hydrophobic pockets separated by shallow polar regions. The depth and shape of these pockets vary among viral families, but the overall architecture is conserved [1]. For example, the HR1 trimer of influenza HA forms a relatively shallow groove compared to the deep, well-defined grooves of the HIV-1 gp41 or the paramyxovirus F protein. This difference in groove geometry influences the size and shape of the small molecules that can bind effectively [2].

Computational Workflow for Structure-Guided Design

The integration of computational and experimental methods is central to the structure-guided design of fusion inhibitors. The following Mermaid diagram illustrates a typical workflow.

flowchart TD
    A[Viral Fusion Protein Structure], > B[Binding Pocket Identification]
    B, > C[Pharmacophore Model Generation]
    C, > D[Virtual Library Screening]
    D, > E[Molecular Docking & Scoring]
    E, > F[Hit Selection]
    F, > G[In Vitro Antiviral Assay]
    G, > H{Active?}
    H, >|Yes| I[Co-crystallization & Binding Mode Confirmation]
    H, >|No| C
    I, > J[Structure-Activity Relationship Studies]
    J, > K[Lead Optimization]
    K, > L[In Vivo Efficacy & Safety Testing]
    L, > M[Clinical Candidate]

The workflow begins with the acquisition of a high-resolution structure of the viral fusion protein, either in its prefusion or postfusion conformation. For class I proteins, the postfusion 6HB structure is often used for peptide inhibitor design, while the prefusion structure is more relevant for small molecule inhibitors that stabilize the native state [1, 2]. Binding pocket identification is performed using computational algorithms that map the solvent-accessible surface and identify cavities with favorable physicochemical properties for ligand binding. Pharmacophore models are then constructed based on the key interactions observed in the binding pocket [1].

Virtual screening of compound libraries, which may contain millions of molecules, is performed using the pharmacophore model as a query. The top-ranked hits are then docked into the binding pocket using molecular docking software. The docking algorithm samples different orientations and conformations of the ligand and scores each pose based on a combination of force field energies, empirical scoring functions, and knowledge-based potentials [2]. The highest-scoring compounds are selected for experimental testing.

In vitro antiviral assays, such as cell-cell fusion inhibition assays or pseudovirus entry assays, are used to confirm the activity of the hits. Active compounds are then co-crystallized with the target protein to obtain an experimental binding mode. This structure is used to guide SAR studies, in which analogs of the hit are synthesized and tested to improve potency, selectivity, and pharmacokinetic properties [2, 3].

Broad-Spectrum Potential and Veterinary Applications

The structural conservation of the fusion machinery across class I viral fusion proteins suggests that inhibitors targeting conserved features of the HR1 groove may exhibit broad-spectrum activity [1]. Gonepudi et al. [1] demonstrated that a single peptide inhibitor could inhibit the entry of multiple paramyxoviruses and coronaviruses by binding to a conserved hydrophobic pocket within the HR1 trimer. The breadth of activity was correlated with the degree of sequence conservation in the binding groove. Viruses with highly conserved HR1 grooves were more susceptible to cross-reactive inhibition [1].

In veterinary medicine, broad-spectrum fusion inhibitors have significant potential for the control of viral diseases in livestock and poultry. For example, an inhibitor that targets the fusion protein of multiple avian paramyxoviruses, including Newcastle disease virus and avian metapneumovirus, could provide a single therapeutic agent for respiratory disease outbreaks in poultry flocks. Similarly, an inhibitor active against both influenza A virus and influenza B virus (which also circulates in some animal species) could be valuable for managing influenza outbreaks in swine and poultry [2].

The development of small molecule fusion inhibitors for veterinary use also offers practical advantages. Oral administration via feed or water is feasible for mass medication of flocks and herds, eliminating the need for individual animal handling. The lower cost of small molecule synthesis compared to peptide production is another important consideration for the veterinary market [2, 3].

Challenges and Future Directions

Despite the promise of structure-guided design, several challenges remain. The hydrophobic nature of the HR1 binding groove makes it difficult to design small molecules with both high affinity and good aqueous solubility. The strategies described by Kuhn et al. [3] for enhancing peptide solubility are also applicable to small molecules, but the structural constraints are more stringent. The introduction of polar groups into a hydrophobic binding pocket can reduce binding affinity if those groups disrupt key van der Waals contacts [3].

Another challenge is the emergence of viral resistance. Mutations in the fusion protein that reduce inhibitor binding can arise under selective pressure. The use of broad-spectrum inhibitors that target highly conserved residues may reduce the likelihood of resistance, but it does not eliminate it entirely [1]. Combination therapy with inhibitors targeting different steps of the viral entry process, such as receptor binding and membrane fusion, may be necessary to achieve durable antiviral effects.

The application of advanced computational methods, including machine learning and free energy perturbation calculations, is expected to accelerate the design of next-generation fusion inhibitors. These methods can more accurately predict binding affinities and identify compounds with optimal pharmacokinetic profiles [2]. The integration of structural data from cryo-electron microscopy, which can capture fusion proteins in their native, membrane-embedded states, will also provide more relevant templates for inhibitor design [1].

Conclusion

Structure-guided design has emerged as a powerful approach for the development of broad-spectrum viral fusion inhibitors. By targeting conserved structural features of class I fusion proteins, peptide and small molecule inhibitors can block the conformational changes required for membrane fusion. The integration of X-ray crystallography, molecular docking, pharmacophore modeling, and in vitro assays provides a rational framework for inhibitor discovery and optimization. The application of these strategies to veterinary viral pathogens holds significant promise for the control of economically important diseases in livestock and poultry. Continued advances in computational methods and structural biology will further enhance the efficiency and breadth of this approach.

References

[1] Gonepudi NK, Baffour Awuah H, Xu W, et al. Structure-Guided Design of Peptide Inhibitors Targeting Class I Viral Fusion Proteins. Pathogens. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41599016/

[2] Xu Y, Anirudhan V, Gaisina IN, et al. Mechanistic insights into the small-molecule inhibition of influenza A virus entry. Proc Natl Acad Sci U S A. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40802690/

[3] Kuhn AJ, Outlaw VK, Marcink TC, et al. Enhancing the solubility of SARS-CoV-2 inhibitors to increase future prospects for clinical development. J Virol. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/39902960/ *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.